On December 30, Gelonghui reported that Guangzhou LBP Medicine Science & Technology (688393.SH) disclosed the record of its investor relations activities, showing that the company's cervical cytology AI-assisted system is in the registration phase for Class III certification. The primary issue this product addresses is the screening of negative cases. There is a notable shortage of pathologists in the country, and cytological diagnosis heavily relies on doctors' interpretations. The expected scenario is that AI can perform most of the negative screenings, allowing doctors to focus their main efforts on suspicious points, thereby improving diagnostic efficiency and accuracy. This product has already annotated over 1 million field images and more than 2.6 million cells, showing high specificity in third-party tests across 9 medical centers. Currently, the company's "cytology reagents + slide staining equipment + scanner + AI interpretation" intelligent overall screening solution has been promoted for trial use in hospital pathology departments, which can alleviate the workload of cytologists. This product has also received the Technology Innovation Award from ASCCP in the USA, and related papers have been published in the academic journals "Modern Pathology" and "Acta Obstetricia et Gynecologica Scandinavica."